GLPwatch

Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis.

Obes Surg · 2025

Last updated 2026-05-28

A review of 8 studies involving 964 patients found that semaglutide led to an average weight loss of about 11% of total body weight, while tirzepatide led to an average loss of about 14% in people who regained weight after weight-loss surgery. Both medications showed statistically significant results, but the confidence in tirzepatide's effect was lower due to wider data ranges.

AI summary of the abstract below.

JournalObes Surg, 2025
Citations1
Molecules semaglutide, tirzepatide
Conditions studied Obesity

Abstract

Fifteen to forty% of patients experience recurrent weight gain (RWG) after metabolic bariatric surgery (MBS). Glucagon-like peptide receptor agonists (GLP-1 RAs) are effective treatments for obesity in nonsurgical patients. To assess the effects of semaglutide and tirzepatide after MBS, we conducted a meta-analysis of data from inception to August 2025. Eight retrospective studies and 964 patients were included. The percentage total weight loss (%TWL) was - 10.97% [95% CI, - 13.41 to - 8.53; p < 0.05] for semaglutide and - 13.63% [95% CI, - 22.59 to - 4.67; p < 0.05] for tirzepatide. The evidence suggests that semaglutide and tirzepatide result in weight reduction in patients with RWG after MBS.

Verbatim abstract via PubMed 41313431 ↗

Related research